# US 2010/0168689 A1 · Systems for providing fluid flow to tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168689 A1
- Document ID: US20100168689A1
- Status: Published application
- Kind: A1
- Application number: 12/648,448
- Filed: 2009-12-29
- Published: 2010-07-01
- Earliest claimed: 2008-12-31
- Assignees: KCI Licensing, Inc.
- Inventors: Larry D. Swain; Michael E. Manwaring; Douglas A. Cornet; Braden K. Leung
- Web page: https://patentgrep.com/patent/US20100168689A1

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61F 2/2846: {Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects (nets or sleeves applied to surface of endoprostheses A61F2/30907; bone plates A61B17/80; bone regeneration in dental surgery A61C8/0006)}
- A61F 13/00063: {comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic (drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00)}
- A61F 13/05: specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61M 1/915: {Constructional details of the pressure distribution manifold}
- A61M 27/00: Drainage appliance for wounds or the like {, i.e. wound drains, implanted drains} ({negative pressure wound therapy devices A61M1/90;} implements for holding wound open A61B17/02 {; middle ear drainage A61F11/202})
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61M 37/0092: {using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61B 17/88: {Osteosynthesis instruments;} Methods or means for implanting or extracting internal {or external} fixation devices {(A61B17/7074 takes precedence)}
- A61F 2002/2835: {Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material}
- A61F 2002/30784: {Plurality of holes}
- A61F 2002/368: {with lateral apertures, bores, holes or openings, e.g. for reducing the mass, for receiving fixation screws or for communicating with the inside of a hollow shaft}
- A61F 2013/00357: {implanted wound fillings or covers}
- A61F 2013/00927: {with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors}
- A61K 49/223: {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- A61M 1/84: {Drainage tubes; Aspiration tips (for negative pressure wound therapy A61M1/90; for surgical cutting instruments A61B17/32)}
- A61M 1/92: {with liquid supply means}
- A61M 2210/02: Bones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Provided is an apparatus that includes a scaffold with a gel or liquid composition deposed on at least a portion of a luminal surface, the gel or liquid composition adapted to include microbubbles. Also provided is a system that includes a source of reduced pressure, the above scaffold, a manifold adjacent the scaffold, and a conduit for providing fluid communication between the manifold and the source of reduced pressure. Additionally provided is a method that includes implanting the above scaffold at the tissue site and disrupting a substantial portion of the microbubbles to induce fluid flow to the scaffold. Further provided is an apparatus that includes a scaffold that comprises a slowly degradable material and a quickly degradable material. Additionally provided is a system for coupling nerve tissue and a microchip assembly.

## Claims

### Claim 1

An apparatus for providing reduced pressure to a wound at a tissue site and facilitating growth of tissue within the wound, the apparatus comprising:
a scaffold for implantation in the wound, the scaffold providing a structure for the growth of the tissue and having a channel therein in fluid communication with the wound;
a chemical substance covering at least a portion of the channel and having a composition adaptable to contain microbubbles; and
a manifold for providing the reduced pressure to the scaffold.

### Claim 2 (depends on 1)

The apparatus of claim 1, wherein the chemical substance is pre-formed with the microbubbles.

### Claim 3 (depends on 1)

The apparatus of claim 1, wherein the chemical substance is operable to form microbubbles in response to a stimulus inducing a gaseous phase transition in the chemical substance.

### Claim 4 (depends on 1)

The apparatus of claim 1, wherein the scaffold is a substantially tubular in shape having a luminal surface forming the channel.

### Claim 5 (depends on 1)

The apparatus of claim 1, wherein the scaffold is a substantially cylindrical shape having a plurality of channels in fluid communication with the wound, a portion of the channels at least partially covered with the chemical substance.

### Claim 6 (depends on 1)

The apparatus of claim 1, wherein the chemical substance comprises a perfluorocarbon.

### Claim 7 (depends on 6)

The apparatus of claim 6, wherein the perfluorocarbon is one of a perfluoropentane (C5F12) or decafluorobutane (C4F10).

### Claim 8 (depends on 1)

The apparatus of claim 1, wherein the chemical substance further comprises an amphiphilic substance.

### Claim 9 (depends on 8)

The apparatus of claim 8, wherein the amphiphilic substance is a block copolymer.

### Claim 10 (depends on 9)

The apparatus of claim 9, wherein the block copolymer is (poly(ethylene oxide)-block-poly(L-lactide)) (PEG-PLLA), poly(ethylene oxide)-block-poly(caprolactone)), or Pluronic P-105.

### Claim 11 (depends on 1)

The apparatus of claim 1, wherein the chemical substance further comprises a bioactive agent.

### Claim 12 (depends on 11)

The apparatus of claim 11, wherein the bioactive agent is at least one of an antibiotic and a growth factor.

### Claim 13 (depends on 11)

The apparatus of claim 11, wherein the bioactive agent is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α (TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage-colony stimulating factor (GM-CSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α (TNF-α) or nerve growth factor (NGF).

### Claim 14

A system for providing reduced pressure to a wound at a tissue site and facilitating growth of tissue within the wound, the system comprising:
a pressure source for supplying the reduced pressure;
a manifold in fluid communication with said pressure source for providing the reduced pressure to the tissue site;
a scaffold in fluid communication with the manifold for delivering the reduced pressure to the wound, said scaffold having a structure to support the growth of tissue within the wound and at least one channel within the structure in fluid communication with the wound, the channel having a luminal surface; and
a chemical substance covering at least a portion of the luminal surface and containing microbubbles adaptable to facilitate a flow of fluid from the wound through the at least one channel within said scaffold.

### Claim 15 (depends on 14)

The system of claim 14, wherein the chemical substance is pre-formed with the microbubbles.

### Claim 16 (depends on 14)

The system of claim 14, wherein the chemical substance is operable to form microbubbles in response to a stimulus inducing a gaseous phase transition in the chemical substance.

### Claim 17 (depends on 14)

The system of claim 14, wherein said scaffold is a substantially tubular shape having one channel in fluid communication with the wound.

### Claim 18 (depends on 14)

The system of claim 14, wherein said scaffold is a substantially cylindrical shape having a plurality of channels in fluid communication with the wound, a portion of the channels having a luminal surface at least partially covered with said chemical substance.

### Claim 19 (depends on 14)

The system of claim 14, wherein the chemical substance comprises a perfluorocarbon.

### Claim 20 (depends on 19)

The system of claim 19, wherein the perfluorocarbon is one of a perfluoropentane (C5F12) or decafluorobutane (C4F10).

### Claim 21 (depends on 14)

The system of claim 14, wherein the chemical substance further comprises an amphiphilic substance.

### Claim 22 (depends on 21)

The system of claim 21, wherein the amphiphilic substance is a block copolymer.

### Claim 23 (depends on 22)

The system of claim 22, wherein the block copolymer is (poly(ethylene oxide)-block-poly(L-lactide)) (PEG-PLLA), poly(ethylene oxide)-block-poly(caprolactone)), or Pluronic P-105.

### Claim 24 (depends on 14)

The system of claim 14, wherein the chemical substance further comprises a bioactive agent.

### Claim 25 (depends on 24)

The system of claim 24, wherein the bioactive agent is at least one of an antibiotic and a growth factor.

### Claim 26 (depends on 24)

The system of claim 24, wherein the bioactive agent is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α (TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage-colony stimulating factor (GM-CSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α (TNF-α), or nerve growth factor (NGF).

### Claim 27 (depends on 14)

The system of claim 14, wherein said scaffold is pre-formed with low-pressure chambers.

### Claim 28

A method for providing reduced pressure to a wound at a tissue site and facilitating growth of tissue within the wound, the method comprising:
utilizing a scaffold having at least one channel within the structure in fluid communication with the wound wherein the channel is at least partially covered by a chemical substance containing microbubbles;
implanting the scaffold in the wound for providing a structure for the growth of the tissue and providing the reduced pressure to the tissue site;
applying reduced pressure to the scaffold and the wound; and
disrupting a substantial portion of the microbubbles to induce the flow of fluids within the scaffold, thereby facilitating the growth of tissue within the wound.

### Claim at position 29

-52. (canceled)
